Article Text

PDF
Extended report
A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance
  1. V Gossye1,
  2. D Elewaut2,
  3. K Van Beneden2,
  4. P Dewint2,
  5. G Haegeman1,
  6. K De Bosscher1
  1. 1
    Ghent University, Department of Physiology, Laboratory for Eukaryotic Gene Expression and Signal Transduction (LEGEST), Gent, Belgium
  2. 2
    Ghent University Hospital, Department of Rheumatology, Gent, Belgium
  1. Correspondence to ProfessorDr G Haegeman, LEGEST, KL Ledeganckstraat 35, B-9000 Gent, Belgium; Guy.Haegeman{at}UGent.be

Abstract

Background: Acquired resistance to glucocorticoids constitutes a major clinical challenge, often overlooked in the search for improved alternatives to classic steroids. We sought to unravel how two glucocorticoid receptor-activating compounds, dexamethasone and Compound A, influence glucocorticoid receptor levels and how this can be correlated to their gene regulatory potential.

Methods: Compound A and dexamethasone were applied in a short-term and long-term treatment protocol. By quantitative PCR analysis in fibroblast-like synoviocytes (FLS) the gene regulatory potential of both compounds in the two experimental conditions was analysed. A parallel Western blot assay revealed the glucocorticoid receptor protein levels in both conditions (ex vivo). In addition, this study examined the effect of systemic administration of dexamethasone and Compound A, in concentrations effective to inhibit collagen-induced arthritis, in DBA/1 mice on glucocorticoid receptor levels (in vivo).

Results: Compound A does not induce a homologous downregulation of glucocorticoid receptor in vivo and ex vivo, thereby retaining its anti-inflammatory effects after prolonged treatment in FLS. This is in sharp contrast to dexamethasone, showing a direct link between prolonged dexamethasone treatment, decreasing glucocorticoid receptor levels, and the abolishment of inflammatory gene repression in FLS. It was also observed that the acquired low receptor levels after prolonged dexamethasone treatment are still sufficient to sustain the transactivation of endogenous glucocorticoid-responsive element-driven genes in FLS, a mechanism partly held accountable for the metabolic side-effects.

Conclusion: Compound A is less likely to evoke therapy resistance, as it does not lead to homologous glucocorticoid receptor downregulation, which is in contrast to classic glucocorticoids.

Statistics from Altmetric.com

Footnotes

  • Funding VG is a predoctoral researcher supported by the Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen. KDB and KVB are postdoctoral fellows with the Fonds voor Wetenschappelijk Onderzoek, Vlaanderen.

  • Competing interests None.

  • Ethics approval The study was approved by the local ethics committee.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.